Abstract 26 Table 1 Comparison of adjusted MACE, mortality, and bleeding at 30 days according to P2Y12-inhibitor.
P2Y12-Inhibitor | MACE n (%) Adjusted HR (95% CI ) | Mortality n (%) Adjusted HR (95% CI ) | Bleeding n (%) Adjusted HR (95% CI ) |
|---|---|---|---|
Clopidogrel (n=1492) | 161 (10.8) | 121 (8.1) | 114 (7.6) |
Ticagrelor (n=737) | 70 (9.5) HR 0.84 (0.53–1.32) vs clopidogrel | 56 (7.6) HR 1.01 (0.57–1.79) vs clopidogrel | 39 (5.3) HR 0.76 (0.41–1.41) vs clopidogrel |
Clopidogrel (n=1492) | 161 (10.8) | 121 (8.1) | 114 (7.6) |
Prasugrel (n=1152) | 61 (5.3) HR 0.82 (0.56–1.20) vs clopidogrel | 41 (6.9) HR 0.95 (0.57–1.57) vs clopidogrel | 59 (5.1) HR 1.25 (0.83–1.87) vs clopidogrel |
Ticagrelor (n=737) | 70 (9.5) | 56 (7.6) | 39 (5.3) |
Prasugrel (n=1152) | 61 (5.3) HR 0.97 (0.60–1.58) vs ticagrelor | 41 (6.9) HR 0.94 (0.50–1.78) vs ticagrelor | 59 (5.1) HR 1.64 (0.88–3.05) vs ticagrelor |